Panion & Bf BiotechTPE:1760 74 EV-to-FCF is 36.50 as of Jul. 11, 2026, which is 20% below its 10-year median of 45.76. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$96.02 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, Panion & Bf Biotech ranks worse than 65.84% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Panion & Bf Biotech's Enterprise Value is NT$5,520 Mil.
Panion & Bf Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$151 Mil. Therefore, Panion & Bf Biotech's EV-to-FCF for today is 36.50.
The historical rank and industry rank for Panion & Bf Biotech's EV-to-FCF or its related term are showing as below:
TPE:1760'
s EV-to-FCF Range Over the Past 10 Years
Min: -2581.97 Med: 45.76 Max: 521.07
Current: 36.96
During the past 13 years, the highest EV-to-FCF of Panion & Bf Biotech was 521.07. The lowest was -2581.97. And the median was 45.76.
TPE:1760's EV-to-FCF is ranked worse than 65.84% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.765
vs TPE:1760: 36.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Panion & Bf Biotech's PE Ratio (TTM) for today is calculated as:
Panion & Bf Biotech's share price for today is NT$62.20.
Panion & Bf Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Panion & Bf Biotech EV-to-FCF Related Terms
Panion & Bf Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1760 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panion & Bf Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panion & Bf Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's EV-to-FCF falls into.
Panion & Bf Biotech's current Enterprise Value is NT$5,520 Mil.
Panion & Bf Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$151 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a EV-to-FCF of 36.50 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Panion & Bf Biotech and its competitors. This is 20% below median its historical median of 45.76. According to the industry distribution chart, Panion & Bf Biotech ranks #370 out of 562 companies in the Drug Manufacturers industry, placing it in the top 65.8%.
Is Panion & Bf Biotech's EV-to-FCF too high?
Panion & Bf Biotech's current EV-to-FCF of 36.50 is 20% below median its 10-year median of 45.76. The Drug Manufacturers industry median EV-to-FCF is 20.77. Panion & Bf Biotech's value of 36.50 is 75.8% above this industry median. Based on the distribution chart, Panion & Bf Biotech ranks #370 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's EV-to-FCF compare to VRTX and REGN?
According to the Drug Manufacturers industry distribution chart, Panion & Bf Biotech ranks #370 out of 562 companies for EV-to-FCF. This places Panion & Bf Biotech in the lower half of its industry. The industry median EV-to-FCF is 20.77. Panion & Bf Biotech's value of 36.50 is 75.8% above this benchmark. While the company's 10-year median is 45.76 vs. the industry median of 20.77, Panion & Bf Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.77, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panion & Bf Biotech's current EV-to-FCF of 36.50 is 75.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Panion & Bf Biotech and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current EV-to-FCF is 36.50, which is 20% below median its own 10-year median of 45.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$96.02, compared to a current price of NT$62.20 — trading 35.2% below its estimated fair value. The current EV-to-FCF is 36.50, which is 20% below median its 10-year median of 45.76 and 75.8% above the Drug Manufacturers industry median of 20.77. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current EV-to-FCF is 36.50 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$62.20 is trading 35.2% below its estimated GF Value™ of NT$96.02.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
EV-to-FCF: 36.50 (20% below median its 10-year median of 45.76)
GF Value™: NT$96.02 vs. price of NT$62.20 (35.2% below fair value)
Industry Position: 75.8% above the Drug Manufacturers median (#370 of 562)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score
Get the complete analysis for TPE:1760
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
